Monitoring Quality of Life Among Prostate Cancer Survivors: The Feasibility of Automated Telephone Assessment - 30/10/12
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/204e.gif)
Résumé |
Objective |
To examine the feasibility of using automated interactive voice response calls to assess prostate cancer survivor quality of life (QOL). In light of an increasing focus on patient-centered outcomes, innovative and efficient approaches to monitor QOL among prostate cancer survivors are increasingly valuable.
Methods |
Forty prostate cancer survivors less than 1 year post-treatment were enrolled at a university-based cancer center clinic from July through August 2011. We adapted the Expanded Prostate Cancer Index Composite (EPIC) survey, a prostate cancer-specific QOL instrument, for use via personal telephone with interactive voice response. We compared written vs interactive voice response EPIC scores across urinary, sexual, bowel, and vitality domains.
Results |
The median age of respondents was 63 years (range, 41-76 years) and the majority had undergone surgery (97.5%). The entire interactive voice response call was completed by 35 participants (87.5%). Over half of all interactive voice response calls were answered after 2 attempts with a median length of 11.3 minutes. On average, interactive voice response EPIC scores were slightly lower than written scores (−2.1 bowel, P = .05; −4.6 urinary incontinence, P < .01). Test-retest reliability was very high for urinary incontinence (r = .97) and sexual function domains (r = .96). Although mean scores were similar for other domains, their distributions had significant ceiling effects limiting our reliability measure interpretation.
Conclusion |
Automated interactive voice response calls are a feasible strategy for assessing prostate cancer survivor QOL. Interactive voice response could provide a low cost, sustainable, and systematic approach to measuring patient-centered outcomes, conducting comparative effectiveness research, and monitoring the quality of prostate cancer care.
Le texte complet de cet article est disponible en PDF.Plan
Financial Disclosure: The authors declare that they have no relevant financial interests. |
|
Funding Support: This study was supported with funding from the Blue Cross Blue Shield of Michigan Foundation and the Prostate Cancer Income Tax Check-Off Fund, administered by the Michigan Department of Community Health. Dr. Skolarus was supported by a National Institutes of Health T32 training grant (NIH 2 T32 DK007782-06). Dr. John Piette is a VA Senior Research Career Scientist. |
|
The contents of this article do not necessarily represent the official views of the Blue Cross Blue Shield of Michigan Foundation or the Michigan Department of Community Health. |
Vol 80 - N° 5
P. 1021-1026 - novembre 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?